SEC Form 3 · accession 0001209191-19-003288
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ran Nussbaum
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 10, 2019 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | holding | — | — | — | 968,525 | I | See Footnote | |
| Ordinary SharesF2 | holding | — | — | — | 452,162 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F3 | $5.00 | holding | — | — | — | — | Jul 27, 2021 | Ordinary Shares | 2,211 | — | I |
| Stock Option (right to buy)F1,F3 | $5.00 | holding | — | — | — | — | Sep 1, 2022 | Ordinary Shares | 2,211 | — | I |
| Stock Option (right to buy)F1,F4 | $5.94 | holding | — | — | — | — | Dec 27, 2022 | Ordinary Shares | 32,723 | — | I |
| Stock Option (right to buy)F1,F5 | $59.23 | holding | — | — | — | — | Jun 4, 2028 | Ordinary Shares | 6,817 | — | I |
| Stock Option (right to buy)F2,F3 | $5.00 | holding | — | — | — | — | Jul 27, 2021 | Ordinary Shares | 1,030 | — | I |
| Stock Option (right to buy)F2,F3 | $5.00 | holding | — | — | — | — | Sep 1, 2022 | Ordinary Shares | 1,030 | — | I |
| Stock Option (right to buy)F2,F4 | $5.94 | holding | — | — | — | — | Dec 27, 2022 | Ordinary Shares | 15,276 | — | I |
| Stock Option (right to buy)F2,F5 | $59.23 | holding | — | — | — | — | Jun 4, 2028 | Ordinary Shares | 3,183 | — | I |
Explanation of responses
- F1The reportable securities are owned by Pontifax (Israel) III Limited Partnership ("Pontifax Israel") . The Reporting Person is a director of Pontifax Israel.
- F2The reportable securities are owned by Pontifax Cayman III Limited Partnership ("Pontifax Cayman") . The Reporting Person is a director of Pontifax Cayman.
- F3Fully vested.
- F433.33% of the shares underlying the stock option vested on each of December 27, 2016, December 27, 2017 and December 27, 2018.
- F525% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will vest 25% on each of March 4, 2019 and June 4, 2019.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney